|
FDA Expands Use of Lilly’s Alimta for Certain Lung Cancer Patients
The FDA has approved Eli Lilly’s Alimta for use as a single agent for continuous maintenance treatment of nonsquamous non-small cell lung cancer (NS NSCLC) based on new clinical data.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives